FRIL, which is overexpressed in high grade glioma, mainly associated with IDH1/2 wildtype and unfavorable prognosis of these glioma patients [113], has also been indicated as a biomarker together with ferritin heavy chain to predict prognosis and temozolomide resistance in glioma patients [114]. This evidence concerns the gene FTH1 and central nervous system cancer.